All In Biotech

Drug Trial Radar · NCT00235508

Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.

Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

420

Actual

Start

Jun 2005

Primary completion

Apr 2006

Study completion Apr 2006

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the safety and efficacy of eszopiclone as adjunctive therapy in the treatment of insomnia in patients with insomnia related to Generalized Anxiety Disorder. All subjects will receive an approved anxiolytic agent and will be randomized to nightly therapy with either eszopiclone or placebo.

Conditions

  • Insomnia
  • Generalized Anxiety Disorder

Interventions

  • Eszopiclone (Lunesta)Drug

    Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change from baseline in subjective sleep latency averaged over the double-blind treatment period.Time frame: 8 weeks

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mesa, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Irvine, California

  • Site not named

    La Mesa, California

  • Site not named

    National City, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    Pasadena, California

  • Site not named

    Redlands, California

  • Site not named

    Riverside, California

  • Site not named

    San Diego, California

  • Site not named

    Farmington, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Coral Springs, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Augusta, Georgia

  • Site not named

    Smyrna, Georgia

  • Site not named

    Northfield, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Baltimore, Maryland

  • Site not named

    Rockville, Maryland

  • Site not named

    Braintree, Massachusetts

  • Site not named

    Brighton, Massachusetts

  • Site not named

    Brockton, Massachusetts

  • Site not named

    Cambridge, Massachusetts

  • Site not named

    Watertown, Massachusetts

  • Site not named

    St Louis, Missouri

  • Site not named

    Kenilworth, New Jersey

  • Site not named

    Piscataway, New Jersey

  • Site not named

    Brooklyn, New York

  • Site not named

    Lawrence, New York

  • Site not named

    New York, New York

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.